Key result
BTK inhibitors linked to increased risk of pericardial effusion and adverse CV outcomes.
Why the study?
Does bruton tyrosine kinase inhibitor therapy increase the risk of pericardial effusion and cardiovascular outcomes in patients with B-cell malignant disease?
Does bruton tyrosine kinase inhibitor therapy increase the risk of pericardial effusion and cardiovascular outcomes in patients with B-cell malignant disease?
This study investigates the potential safety signal of pericardial effusion and cardiovascular outcomes associated with Bruton tyrosine kinase inhibitors in B-cell malignancies.
Answers are grounded in this paper and cite their sources.
May warrant closer pericardial monitoring with BTKi; hypothesis-generating and requires randomized confirmation.
This cohort study examines the association of bruton tyrosine kinase inhibitor therapy in B-cell malignant disease with increased risk of pericardial effusion and cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Zanco et al. (2026) studied this question. Bruton tyrosine kinase inhibitor therapy in B-cell malignancies is associated with an increased risk of pericardial effusion and adverse cardiovascular outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: